Metis TechBio Co., Ltd.
Research Metis TechBio Co., Ltd. (7666.HK) on Bullrun: market cap HKD 14.10B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7666.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 14.10B
- Financial periodFY2025
- RevenueCNY 105.00M
- Revenue growth6985.0%
- Net income-CNY 391.84M
- Free cash flow-CNY 140.63M
- Gross margin98.2%
Valuation Snapshot
latest market cap is HKD 14.10B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 105.00M | -CNY 391.84M | -CNY 140.63M | 98.2% | -0.34 | CNY 828.26M | CNY 131.13M | CNY 1.04B |
| FY2024 | CNY 1.48M | -CNY 499.20M | -CNY 242.85M | 55.5% | -0.43 | CNY 557.64M | CNY 93.02M | -CNY 1.38B |
| FY2023 | CNY 9.34M | -CNY 581.93M | -CNY 248.89M | 59.8% | -0.5 | CNY 561.47M | CNY 129.21M | -CNY 977.56M |
| FY2022 | CNY 554.00K | -CNY 512.53M | -CNY 196.22M | 56.1% | -0.44 | CNY 364.47M | CNY 670.93M | -CNY 90.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 14.10B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Metis TechBio Co., Ltd.
Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. It develops NanoForge, a suite of synergistic technologies that includes novo lipid library, AI foundational models, METiSAIAgent, quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Metis TechBio Co., Ltd.'s market cap?
Metis TechBio Co., Ltd.'s market capitalization is HKD 14.10B.
What does Metis TechBio Co., Ltd. do?
Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. It develops NanoForge, a suite of synergistic technologies that includes novo lipid library, AI foundational models, METiSAIAgent, quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms.